ARTICLE | Management Tracks
Misciattelli becomes CEO of Aavantgarde
Plus new CMO, SVP of clinical development at Alumis, and updates from Vertex, Third Rock, AiCuris and more
September 9, 2022 12:13 AM UTC
Milan-based Aavantgarde Bio s.r.l. named Natalia Misciattelli CEO. Misciattelli was CBO at NovalGen Ltd., before which she was SVP of strategy and operations of Freeline Therapeutics Holdings plc (NASDAQ:FRLN). Aavantgarde is developing AAV-based vector therapies for inherited retinal disorders.
Autoimmune disease company Alumis Inc. hired Jörn Drappa as CMO and Roman Rubio as SVP of clinical development and translational medicine. Drappa was CMO at Ventyx Biosciences Inc. (NASDAQ:VTYX), before which he founded Viela Bio Inc., where he was head of R&D and CMO. Rubio was SVP of clinical development at Revance Therapeutics Inc. (NASDAQ:RVNC)...